SpringWorks Therapeutics Inc Stock

$46.98

0.02% yesterday

Nasdaq, Jun 27, 10:17 pm CET

ISIN

US85205L1070

Symbol

SWTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

SpringWorks Therapeutics Inc Stock price

$46.98

+4.98 11.86% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.01 0.02%

ISIN

US85205L1070

Symbol

SWTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$3.5b

Enterprise Value

$3.3b

Net debt

$-287.9m

Cash

$287.9m

Shares outstanding

75.0m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

16.11 | 10.60

EV/Sales

14.80 | 9.74

EV/FCF

negative

P/B

8.44

Financial Health

Equity Ratio

81.92%

Return on Equity

-53.65%

ROCE

-62.57%

ROIC

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$219.7m | $334.1m

EBITDA

$-260.9m | $-183.3m

EBIT

$-264.7m

Net Income

$-253.9m | $-210.4m

Free Cash Flow

$-185.6m

Growth (TTM | estimate)

Revenue

730.51% | 74.36%

EBITDA

26.94% | 33.26%

EBIT

26.31%

Net Income

25.11% | 18.51%

Free Cash Flow

24.22%

Margin (TTM | estimate)

Gross

93.23%

EBITDA

-118.77% | -54.87%

EBIT

-120.52%

Net

-115.60% | -62.97%

Free Cash Flow

-84.48%

EPS

$-3.41

FCF per Share

$-2.47

Short interest

10.18%

Employees

368.00

Rev per Employee

$520.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

SpringWorks Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a SpringWorks Therapeutics Inc forecast:

8x Hold

73%

3x Sell

27%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a SpringWorks Therapeutics Inc forecast:

Hold

73%

Sell

27%

Analyst Estimates with Stock Price Targets

Financial data from SpringWorks Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	220 220	731% 731% 100%
- Direct Costs	15 15	819% 819% 7%
Gross Profit	205 205	725% 725% 93%
- Selling and Administrative Expenses	273 273	28% 28% 124%
- Research and Development Expense	196 196	15% 15% 89%
EBITDA	-261 -261	27% 27% -119%
- Depreciation and Amortization	3.84 3.84	79% 79% 2%
EBIT (Operating Income) EBIT	-265 -265	26% 26% -121%
Net Profit	-254 -254	25% 25% -116%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

SpringWorks Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

8 days ago

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

– If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors –

Neutral

Business Wire

●

24 days ago

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SpringWorks Therapeutics, Inc. (NasdaqGS: SWTX) to Merck KGaA, Darmstadt, Germany. Under the terms of the proposed transaction, shareholders of SpringWorks will receive $47.00 in cash for each shar...

Neutral

GlobeNewsWire

●

about one month ago

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN –

More SpringWorks Therapeutics Inc News

Company Profile

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in applying a precision medicine approach to acquiring, developing and commercializing medicines. It focuses on developing drugs for underserved patient populations suffering from devastating rare diseases and cancer. Its pipeline include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.

Head office	United States
CEO	Saqib Islam
Employees	368
Founded	2017
Website	www.springworkstx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now